|| List of recent Vaccine-related patents
| Novel polymavirus associated with diarrhea in children|
Provided is a new polyomavirus, provisionally named mx polyomavirus, (mxpyv). Further provided are cdna nucleic acid sequences, recombinant proteins, expression vectors and host cells, recombinant anti-mxpyv antibodies, vaccines, compositions, methods of detecting mxpyv, methods for assaying for anti-mxpyv compounds, and methods for treating or preventing a mxpyv infection..
| Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection|
The present invention encompasses methods and compositions for ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for ureaplasma, including dna vaccines.
| Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines|
The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is gap-dmorie..
| Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins|
The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens.
| Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof|
A vaccine comprising an immunologically effective amount of recombinant modified vaccinia ankara (rmva) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified h5 (mh5) promoter operably linked to a dna sequence encoding a heterologous foreign protein antigen, wherein the expression of said dna sequence is under the control of the mh5 promoter; b) generating rmva virus by transfecting one or more plasmid vectors obtained from step a) into wild type mva virus; c) identifying rmva virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rmva virus strain identified by step d); and f) purifying the rmva viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (cmv) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of immediate-early gene-1 or immediate-early gene-2 (iefusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine..
|Vaccines against chlamydial infection|
The present invention relates to compositions comprising proteins or polynucleotides of chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of chlamydia infection.. .
|Liquid stable virus vaccines|
The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines..
|Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a|
The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..
This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided..
|Cells and methodology to generate non-segmented negative-strand rna viruses|
The present invention relates to recombinant cells as well as to methods for the generation of non-segmented negative-sense single-stranded rna viruses (nnv or mononegavirales) from cloned deoxyribonucleic acid (cdna), especially from measles virus and in particular from attenuated strains such as those approved for vaccination, in particular from the attenuated schwarz measles virus and various recombinant schwarz measles-based viruses expressing heterologous sequences. Such rescued viruses can be used, after amplification, as vaccines for immunization against measles and/or against the heterologous peptides or proteins expressed..
|Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases|
The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity.
|Replication-defective arenavirus vectors|
The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (gp), nucleoprotein (np), matrix protein z and rna-dependent rna polymerase l are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral rna-dependent rna polymerase, cellular rna polymerase i, rna polymerase ii or rna polymerase iii.
|Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use|
The present invention relates to novel hemagglutinin h5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such h5 proteins, nucleic acids or vectors encoding for those h5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals..
|Polyionic papilloma virus-like particle (vlp) vaccines|
The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle (vlp) vaccines.
|Mesothelin vaccines and model systems|
Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic t cell response.
|Replication deficient influenza virus for the expression of heterologous sequences|
The present invention relates to a novel replication deficient influenza virus comprising a modified ns1 segment coding for a ns1 protein lacking a functional rna binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the ns gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines.
|Novel strategies for improved cancer vaccines|
The present invention concerns methods and compositions for forming anti-cancer vaccine complexes. In preferred embodiments, the anti-cancer vaccine complex comprises an antibody moiety that binds to dendritic cells, such as an anti-cd74 antibody or antigen-binding fragment thereof, attached to an ad (anchoring domain) moiety and a xenoantigen, such as cd20, attached to a ddd (dimerization and docking domain) moiety, wherein two copies of the ddd moiety form a dimer that binds to the ad moiety, resulting in the formation of the vaccine complex.
|Vaccines against clostridium difficile and methods of use|
Attenuated microorganisms expressing clostridium difficile antigen(s), and methods of using the same for vaccination of patients are disclosed the invention provides an attenuated microorganism expressing an immunogenic portion of a c difficile toxin a c-terminal repeat region and/or a c difficile toxin b c-terminal repeat region the microorganism is an attenuated salmonella comprising an integrated gene expression cassette that directs the expression of the immunogenic peptide from an in vivo inducible promoter.. .
|Influenza a virus vaccines and inhibitors|
The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (cpsf30) binding site on the surface of the influenza a non-structural protein 1 (ns1). Specifically, critical biochemical reagents, conditions for crystallization and nmr analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza a (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development..
The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies.
|Displaying native human ige neutralizing fcerla-contacting ige b-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold|
Vaccine displaying native antigenic loops of immunoglobulin e is critical for eliciting neutralizing anti-ige antibodies. The embodiment of the invention enables the display of native antigenic ige receptor-contacting loops as ige b-cell vaccines via three steps of constraining methods.
|Mammalian cell lines for increasing longevity and protein yield from a cell culture|
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis.
|Vaccine composition containing synthetic adjuvant|
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (gla) that is provided in substantially homogeneous form. Chemically defined, synthetic gla offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants.
|Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same|
For the first time, an o-specific polysaccharide antigen that is a shigella sonnei, phase i, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural compound in the form of a bacterial capsular polysaccharide. The exopolysaccharide contains a non-toxic lipid component, namely non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity.
|Adjuvants that activate adaptive immune system by stimulating nlrp3|
A method of identifying an agent, or combination of agents, as a candidate immunological adjuvant is provided comprising contacting a cell comprising a nod-like receptor (nlrp3) with the agent. Methods of enhancing immune responses to vaccines are also provided..
|Hiv/siv vaccines for the generation of mucosal and systemic immunity|
Compositions of genetically engineered, secreted gp96 (gp69-ig) induced strong mucosal and systemic immune responses and cd8 expansion that was independent of cd4 help. Immunization of patients with gp96-ig immunization is especially attractive for induction of mucosal and systemic immunity to siv/hiv and other diseases..
|Hiv-1 envelope glycoprotein|
The present application relates to novel hiv-1 envelope glycoproteins which may be utilized as an hiv-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
|Immunization of avians by administration of non-replicating vectored vaccines|
The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians.
The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies.
|Peptide and conjugate vaccines for fungal infections|
Several new peptides have been developed that show effectiveness as vaccines against candidiasis and other fungal diseases. A new conjugate vaccine of a β-mannotriose linked to a fungal peptide linked to tetanus toxin has been shown to be effective as a vaccine with or without use of an adjuvant.
|Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies|
The present invention relates to compositions, kits, and methods for preparing an autologous idiotype vaccine, or autologous anti-idiotype vaccine, for treatment of a b-cell malignancy based on the isotype(s) (class(es)) of immunoglobulins expressed by the malignancy; methods for treating b-cell malignancies; and methods for selecting a treatment for a subject having a b-cell malignancy.. .
|Cell-based, anti-cancer vaccines|
The present invention relates to cancer vaccines and more particularly to compositions and methods for producing activated antigen presenting cells (dendritic cells, macrophages, monocytes, or other cells capable of presenting antigen to t lymphocytes); to pharmaceutical compositions including such cells; and to methods of using such cells (e.g., in treating patients who are suffering from or at risk of developing cancer).. .
|Modified influenza virus for monitoring and improving vaccine efficiency|
The immunogenicity of the influenza virus hemagglutinin (ha) molecule may be increased by substitutions of amino acids in the ha sequence. The substitution of specific ha residues, such as asparagine at position 223 of h5 ha, increase the sensitivity of the hemagglutinin inhibition (hi) assay by altering receptor specificity and/or antibody-antigen binding.
|Process for producing an immunogenic composition containing tetanus toxoid|
The present invention relates to the field of vaccines for protecting against tetanus, and in particular processes for the production of vaccines comprising tetanus toxoid adsorbed onto aluminium salts. Processes are provided whereby tetanus toxoid is absorbed onto aluminium salt adjuvant having defined characteristics for optimal results..
A method for enhancing a vaccine therapy effect by a vaccine composition. The method including a step of implanting β-tricalcium phosphate in an inside of a body of a subject, and a step of administering the vaccine composition to the subject at the same time with or before or after the implanting step..
|Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof|
An infectious clone based on the genome of a wild-type rna virus is produced by the process of providing a host cell not susceptible to infection by the wild-type rna virus, providing a recombinant nucleic acid based on the genome of the wild-type rna virus, transfecting the host cell with the recombinant nucleic acid and selecting for infectious clones. The recombinant nucleic acid comprises at least one full-length dna copy or in vitro-transcribed rna copy or a derivative of either.
|Enolase peptide conjugate vaccines against staphylococcus aureus|
The present invention relates to peptides of the enolase protein from staphylococcus aureus as well as nucleic acid and nucleic acid sequence homologues encoding the peptides. The present invention also relates to a composition, particularly a s.
|Zona pellucida binding peptides, expression vectors, compositions, and methods for species-specific immunocontraception of animals|
Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines..
|Vaccines directed to langerhans cells|
The present invention includes isolated anti-langerin vaccines, methods for making and using an isolated anti-langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-langerin antigen delivery vectors and their manufactures and use..
|Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors|
The present invention relates to enhancing, modulating or stimulating the immune response to mmp-2 expressing tumors, including melanoma, and to the modulation and application of immune modulators and mmp-2 peptides for melanoma or other mmp-2 expressing tumor vaccines. The invention provides methods and means to activate an effective response to mmp-2 expressing tumors and modulate the ability of mmp-2 to skew cd4+ t cell responses toward that of th2 cells, which are less effective mediators of tumor cell clearance than th1 cells.
|Novel adenine derivatives|
N is an integer having a value of 1 to 6; het is a 6-membered saturated heterocycle containing one nitrogen atom wherein het is attached to the —(ch2)n— moiety at any carbon atom of the heterocycle; r3 is hydrogen, c1-8alkyl, or c3-7cycloalkylc0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..
|Vaccine against pasteurellaceae|
The invention relates to vaccines providing protection against infections caused by members of the pasteurellaceae family comprising outer membrane vesicles as the only active components, wherein the outer membrane vesicles are obtained from one or more strains of the pasteurellaceae family, with the proviso that hypervesiculating strains are excluded. The invention also relates to a method for preparing such a vaccine..
|Attenuated swine influenza vaccines and methods of making and use thereof|
This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode ha proteins having additional glycosylation sites, relative to the ha proteins encoded by the corresponding virulent parental viruses.
|Influenza hemagglutinin and neuraminidase variants|
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.. .
|Live attenuated virus vaccines for la crosse virus and other bunyaviridae|
The invention relates to vaccine compositions including cev serogroup immunogens, attenuated and inactivated viruses of the cev serogroup and chimeric bunyaviridae. Also disclosed are methods of treating or preventing cev serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a cev serogroup immunogen, methods for detecting la crosse virus (lacv) infection in a biological sample and infectious chimeric bunyaviridae..
|Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof|
Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of herpes virus antigens, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against herpes virus using the vaccines that are provided..
|Tomm34 peptides and vaccines including the same|
The present invention provides isolated peptides or the fragments derived from seq id no: 42, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences.
|Cancer vaccine composition|
A cancer vaccine composition for human leukocyte antigen (hla)-a*0206-positive persons, comprising a protein product of the tumor suppressor gene wt1 or a partial peptide thereof.. .
|Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same|
Provided herein are nucleic acid sequences that encode novel consensus amino acid sequence of hbv core protein, as well as genetic constructs/vectors and vaccines that express said protein sequences. Also provided herein are methods for generating an immune response against hbv using the nucleic acid sequences that are provided..
|Sulfonamides as hib protease inhibitors|
Compounds of formula i are disclosed: wherein l, a, r1, r2, r3a, r3b, r4a, r4b, r5, r6 and r7 are defined herein. The compounds encompassed by formula i include compounds which are hiv protease inhibitors and other compounds which can be metabolized in vivo to hiv protease inhibitors.
|Hiv protease inhibitors|
Compounds of formula i are disclosed wherein r1, r2, r3a, r3b, r4a, r4b, r5a, r5b, r6a, r6b, r8 and r9 are defined herein. The compounds encompassed by formula i include compounds which are hiv protease inhibitors and other compounds which can be metabolized in vivo to hiv protease inhibitors.
|Cna-b domain antigens in vaccines against gram positive bacteria|
The invention provides protective antigens which are useful in vaccine compositions to induce protection against gram positive bacteria, particularly against s. Agalactiae, s.
|Adenovirus serotype 26 and serotype 35 filovirus vaccines|
Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection..
|Protein complex system for increased immunogenicity and functionality, and methods making and use|
Genes for proteins which spontaneously form dimers and/or oligomers can be recombinantly linked together, which upon expression in e. Coli produces stable dimeric fusion proteins that spontaneously self-assemble into enormous, polyvalent complexes having increased immunogenicity and functionality.
|Composition and methods for detecting or preventing lawsonia intracellularis infections|
The invention relates to vaccines for preventing lawsonia intracellularis infections and tests for the detection of the presence of l. Intracellularis antibodies in biological samples.
|Immunotherapy against erbb-3 receptor|
The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid dna and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the erbb-3 receptor.
|Compounds for preparing immunological adjuvant|
And stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates..
|Pol i promoter derived from vero cells and recombinant vector containing same|
The present invention relates to a pol i promoter derived from vero cells and a recombinant vector containing the same. When the pol i promoter derived from vero cells according to the present invention is utilized, viruses can be manufactured efficiently, and consequently, the manufacture of both seasonal influenza vaccine and pandemic vaccine can be prepared more quickly to usefully address either situation..
|Engineered pertactin variants for vaccine use|
The present invention is related with the field of biomedicine. It comprises the engineering of the pertactin protein (prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against bordetella pertusis.
|Actinobacillus suis antigens|
The invention provides immunogenic compositions useful for inhibiting, treating, protecting, or preventing infection by actinobacillus suis. These immunogenic compositions are demonstrated to usefully stimulate immunogenic responses in treated pigs.
|Methods for producing virus particles with simplified glycosylation of surface proteins|
Methods for production of virus particles with simplified glycosylation on structural or surface proteins are provided. When used as targets for vaccine production, the conserved nature of such sites generates vaccines that are less sensitive to viral mutations.